Market Overview

UPDATE: JP Morgan Reiterates The Cooper Companies at Overweight Post Model Update

Related COO
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
With New CEO In Place, Focus For Teva Pharma Turns To 'Execution'

JP Morgan reiterated its Overweight rating on The Cooper Companies (NYSE: COO) and maintained its price target at $106.

JP Morgan commented, "We are updating our Cooper model to reflect the company's revised royalty agreement with Ciba, announced on December 21. For FY13, we are raising our EPS estimate by $0.15 to $6.00, including quarterly estimates of $1.20, $1.41, $1.65, and $1.74. Looking out to FY14, we are lifting our EPS forecast to $6.68 versus our prior $6.51 estimate, in both cases reflecting a lower royalty rate to Ciba on silicone hydrogel lens sales, offset in part by incremental investment in the business."

The Cooper Companies closed at $91.89 on Wednesday.

Latest Ratings for COO

Jul 2017KeyBancDowngradesOverweightSector Weight
Jun 2017GuggenheimInitiates Coverage OnNeutral
Dec 2016Wells FargoUpgradesMarket PerformOutperform

View More Analyst Ratings for COO
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (COO)

View Comments and Join the Discussion!

Partner Center